John R. Penrod, PhD


Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States

August 24, 2021

This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.